Literature DB >> 28648953

Synthesis of thiazole linked indolyl-3-glyoxylamide derivatives as tubulin polymerization inhibitors.

Sravanthi Devi Guggilapu1, Lalita Guntuku2, T Srinivasa Reddy3, Atulya Nagarsenkar1, Dilep Kumar Sigalapalli1, V G M Naidu2, Suresh K Bhargava3, Nagendra Babu Bathini4.   

Abstract

A series of thiazole linked indolyl-3-glyoxylamide derivatives were synthesized and evaluated for their in vitro cytotoxic activity against DU145 (prostate), PC-3 (prostate), A549 (lung) and HCT-15 (colon) cancer cell lines by employing the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Among all the synthesized compounds, compound 13d displayed cytotoxicity of IC50 = 93 nM towards DU145 cancer cell line. The most active compound 13d was also tested on RWPE-1 cells and was found to be safe compared to the DU145 cells. The target compounds were also evaluated for their inhibition activity of tubulin polymerization. Further, the treatment of compound 13d on DU145 cells led to the inhibition of cell migration ability. The detailed studies such as acridine orange/ethidium Bromide (AO/EB), DAPI, annexin V-FITC/propidium iodide staining assay suggested that the compound 13d induced apoptosis in DU145 cells. The influence of the cytotoxic compound 13d on the cell cycle distribution was assessed on the DU145 cell line, exhibiting a cell cycle arrest at the G2/M phase. Moreover, the treatment with compound 13d caused collapse of mitochondrial membrane potential and elevated intracellular ROS levels in DU145 cells. The results from molecular modelling studies revealed that these compounds bind at the colchicine binding site of the tubulin. Thus, this new molecular scaffold could be a new lead for the development of anticancer agents that target tubulin.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anticancer; Apoptosis; Indolyl-3-glyoxylamide; Thiazole; Tubulin polymerization inhibitor

Mesh:

Substances:

Year:  2017        PMID: 28648953     DOI: 10.1016/j.ejmech.2017.06.025

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  6 in total

1.  Synthesis and biological evaluation of 2-aryl-benzimidazole derivatives of dehydroabietic acid as novel tubulin polymerization inhibitors.

Authors:  Ting-Ting Miao; Xu-Bing Tao; Dong-Dong Li; Hao Chen; Xiao-Yan Jin; Yi Geng; Shi-Fa Wang; Wen Gu
Journal:  RSC Adv       Date:  2018-05-16       Impact factor: 4.036

2.  Molecular docking studies, biological evaluation and synthesis of novel 3-mercapto-1,2,4-triazole derivatives.

Authors:  Javad Ghanaat; Mohammad A Khalilzadeh; Daryoush Zareyee
Journal:  Mol Divers       Date:  2020-02-17       Impact factor: 2.943

3.  Design, synthesis and antiproliferative evaluation of novel sulfanilamide-1,2,3-triazole derivatives as tubulin polymerization inhibitors.

Authors:  Shewei Guo; Yingwei Zhen; Mengguo Guo; Longzhou Zhang; Guosheng Zhou
Journal:  Invest New Drugs       Date:  2018-07-18       Impact factor: 3.850

4.  Synthesis and biological evaluation of oxazinonaphthalene-3-one derivatives as potential anticancer agents and tubulin inhibitors.

Authors:  Salimeh Mirzaei; Maqsudjon Qayumov; Fahimeh Gangi; Javad Behravan; Razieh Ghodsi
Journal:  Iran J Basic Med Sci       Date:  2020-11       Impact factor: 2.699

5.  In Silico Exploration of Novel Tubulin Inhibitors: A Combination of Docking and Molecular Dynamics Simulations, Pharmacophore Modeling, and Virtual Screening.

Authors:  Farzin Hadizadeh; Razieh Ghodsi; Salimeh Mirzaei; Amirhossein Sahebkar
Journal:  Comput Math Methods Med       Date:  2022-01-15       Impact factor: 2.238

6.  Design, synthesis, docking study and anticancer evaluation of new trimethoxyphenyl pyridine derivatives as tubulin inhibitors and apoptosis inducers.

Authors:  Mohamed Hagras; Asmaa A Mandour; Esraa A Mohamed; Eslam B Elkaeed; Ibrahim M M Gobaara; Ahmed B M Mehany; Nasser S M Ismail; Hanan M Refaat
Journal:  RSC Adv       Date:  2021-12-13       Impact factor: 4.036

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.